In vitro experiments assessing PyDau release under simulated tumor conditions and in plasma (Supplementary Figures S8–S9), together with in vivo studies of intratumoral accumulation and pharmacokinetics (Supplementary Figure S10), indicate that LiPyDau achieves more sustained tumor retention and slower release kinetics than the clinically used PLD formulation—factors that likely contribute to its pronounced antitumor efficacy. Here, GPLD1 is linked to neoplasm.